Safety and Efficacy of Letetresgene Autoleucel Alone or With Pembrolizumab for Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
Blood Adv 2022 Dec 19;[EPub Ahead of Print], T Nishihori, JE Hoffman, A Huff, GS Kapoor, I Eleftheriadou, S Zajic, A Urbano, S Suchindran, MJ Chisamore, JW D'Souza, T Faitg, AP RapoportFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.